Substance P and Chronic Pain in Patients with Chronic Inflammation of Connective Tissue

Lisowska, Barbara; Lisowski, A.; Siewruk, Katarzyna

doi:10.1371/journal.pone.0139206

Cited by 36 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, the conclusion that SP levels are not associated with pain history should be interpreted with caution. Chronic elevation of SP may be a better marker of chronic pain (Lisowska et al , 2015) that is often managed at home and this was not assessed in our study.…”

Section: Discussionmentioning

confidence: 97%

Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use

et al. 2016

View full text Add to dashboard Cite

Summary Sickle cell disease (SCD) pain transitions from acute to chronic for unknown reasons. Chronic elevation of the pain neurotransmitter substance P (SP) sensitizes pain nociceptors. We evaluated SP levels in controls and SCD patients during baseline and acute pain and investigated associations between SP and age, gender, pain history, haemolysis and hydroxycarbamide (also termed hydroxyurea) use. Plasma SP levels were measured using enzyme-linked immunosorbent assay. Independent samples t-test compared SP levels between: 1) SCD baseline and controls and 2) SCD baseline and acute pain. Multivariate linear regression determined associations between SP and age, gender, pain history and hydroxycarbamide use. Spearman correlation determined an association between SP and haemolysis. We enrolled 35 African American controls, 25 SCD baseline and 12 SCD pain patients. SCD patients were 7-19 years old. Mean±standard deviation SP level (pg/ml) in SCD baseline was higher than controls (32.4±11.6 vs. 22.9±7.6, P=0.0009). SP in SCD pain was higher than baseline (78.1±43.4 vs. 32.4±11.6, P=0.004). Haemolysis correlated with increased SP: Hb (r=−0.7, P=0.0002), reticulocyte count (r=0.61, P=0.0016), bilirubin (r=0.68, P=0.0216), LDH (r=0.62, P=0.0332), aspartate aminotransferase (r=0.68, P=0.003). Patients taking hydroxycarbamide had increased SP (β=29.2, P=0.007). SP could be a mediator of or marker for pain sensitization in SCD and a biomarker and/or target for novel pain treatment.

show abstract

Section: Discussionmentioning

confidence: 97%

Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Chronic inflammation is a common symptom in OA (osteoarthritis) and RA. A study by Barbara et al (61) found that serum SP concentration in patients with OA and RA was positively correlated with the intensity of chronic pain.…”

Section: Chronic Inflammationmentioning

confidence: 99%

The Role of Substance P in the Regulation of Bone and Cartilage Metabolic Activity

Lin

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Substance P (SP) is a neuropeptide that is released from sensory nerve endings and is widely present in nerve fibers. It acts on bones and related tissues by binding to receptors, thereby regulating bone metabolism, cartilage metabolism, and fracture healing. SP has attracted widespread attention as a signaling substance that can be recognized by both the immune system and the nervous system. Previous studies have shown that bone and chondrocytes can synthesize and secrete sensory neuropeptides and express their receptors, and can promote proliferation, differentiation, apoptosis, matrix synthesis, and the degradation of target cells through autocrine/paracrine modes. In this paper, we review the research progress made in this field in recent years in order to provide a reference for further understanding the regulatory mechanism of bone and cartilage physiology and pathological metabolism.

show abstract

“…SP is a crucial mediator of inflammation, and plays a key role in the generation and maintenance of inflammation. It is involved in the pathophysiology of various inflamatory diseases such as rheumatoid arthritis and joint inflammation (11,12). SP participates in the inflammatory processes by inducing the release of proinflammatory cytokines such as IL-1, IL-2 and TNF-α from various cells (13).…”

Section: The Comparison Of Effects Of Applications Of Compound 48/80 mentioning

confidence: 99%

The comparison of effects of applications of compound 48/80 and mast cell mediator suspension on inflammation in rats: A methodological study for acute inflammatory pain

Kılınç¹,

Dağıstan²,

Çetinkaya³

et al. 2018

Clin Exp Health Sci

View full text Add to dashboard Cite

Objective: Inflammation underlies the pathological basis of most diseases. Substance-P is a key mediator that participates in various inflammatory processes and painful conditions. Mast cells (MCs) have a key role in inflammatory processes via mediators released from their granules. The experimental models for the investigation of pathogenesis and treatment of inflammatory diseases represent merely certain characteristics of inflammatory cases, therefore, more comprehensive models are required. We aimed to compare effects of administrations of the compound-48/80 and mast cell mediator suspension (MCMS) obtained from peritoneal MCs on the inflammation in rats. Methods: Rats were divided into five groups (n=6): Intraperitoneally, Control group received 0.2 ml saline; C-48/80 group received 2 mg/kg compound-48/80; MCMS group received 0.2 ml MCMS; Cr+C-48/80 group received 10 mg/kg cromolyn plus compound-48/80; Cr+MCMS group received cromolyn plus MCMS. Potent inflammatory markers, plasma substance-P levels, and number and degranulation of dural MCs were measured. Data were analyzed using one-way ANOVA followed by Dunnett's post hoc test. Results: Compound-48/80 increased plasma substance-P levels (p<0.05) and dural MC-degranulation (p<0.001). Likewise, MCMS increased substance-P levels and dural MC-degranulation (p<0.001) as well as number of dural MCs (p<0.01). MC stabilizer cromolyn inhibited increases in the parameters induced by compound-48/80 and MCMS (p<0.01 and p<0.05, respectively). Conclusion: MCMS administration had greater impact to increase the plasma substance-P levels and number and degranulation of dural MCs than that of the compound-48/80 administration. The results demonstrate the potent inflammatory effect of MCMS treatment over the compund-48/80 administration. Administration of MCMS could be a useful tool to study inflammatory conditions.

show abstract

Substance P and Chronic Pain in Patients with Chronic Inflammation of Connective Tissue

Cited by 36 publications

References 28 publications

Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use

Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use

The Role of Substance P in the Regulation of Bone and Cartilage Metabolic Activity

The comparison of effects of applications of compound 48/80 and mast cell mediator suspension on inflammation in rats: A methodological study for acute inflammatory pain

Contact Info

Product

Resources

About